Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-02-28 · accession 0001600620-25-000022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-04 | 2025-03-03 | AUPH | Keenan Greg | Chief Medical Off | S - Sale | $8.00 | -12.2K | 161.8K | -7% | -$97.9K |
| D | 2025-03-04 | 2025-02-28 | AUPH | Keenan Greg | Chief Medical Off | A - Grant | $0.00 | +62.6K | 174.0K | +56% | $0 |
| D | 2025-03-04 | 2025-02-28 | AUPH | Keenan Greg | Chief Medical Off | A - Grant | $0.00 | +95.6K | 95.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-03 | S | D | 12,239 | $8.00 | 161,789 | D | — | — | (F2) Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of Restricted Stock Units related to the January 30, 2024 grant. (F3) The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.79 to $8.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 2 | Common | Common Stock | 2025-02-28 | A | A | 62,583 | $0.00 | 174,028 | D | — | — | (F1) Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2025-02-28 | A | A | 95,570 | $0.00 | 95,570 | D | $7.55 · — to 2035-02-28 | 95,570 Common Stock | (F4) One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. |